Page last updated: 2024-09-02

carboxyamido-triazole and Carcinoma, Non-Small Cell Lung

carboxyamido-triazole has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L	1
Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ	1
Adjei, AA; Bauman, MD; Bernath, AM; Fitch, TR; Graham, DL; Hauge, MD; Hillman, SL; Jett, JR; Johnson, EA; Kugler, JW; Mandrekar, SJ; Marks, RS; Moore, DF; Perez, EA; Soori, GS; Windschitl, HE; Wos, EJ	1

Trials

1 trial(s) available for carboxyamido-triazole and Carcinoma, Non-Small Cell Lung

Article	Year
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Placebos; Quality of Life; Triazoles	2008

Article

Year

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:2

Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Placebos; Quality of Life; Triazoles

2008

Other Studies

2 other study(ies) available for carboxyamido-triazole and Carcinoma, Non-Small Cell Lung

Article	Year
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays	2017
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult	2010

Article

Year

Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.

The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2017

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18

Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult

2010